Sign In
Buy OFIX
$11.80
+0.0100 (+0.0848%)
At Close: Jul 31, 2026
Orthofix Reports Third Quarter 2025 Financial Results
07:00am, Tuesday, 04'th Nov 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 202
Orthofix Medical Inc. (NASDAQ:OFIX) Given Consensus Recommendation of “Moderate Buy” by Analysts
01:31am, Sunday, 26'th Oct 2025
Orthofix Medical Inc. (NASDAQ: OFIX - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rat
Orthofix to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 15'th Oct 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and
Orthofix to Report Third Quarter 2025 Financial Results
07:00am, Tuesday, 14'th Oct 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2025 financial results on T
FMS vs. OFIX: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 07'th Oct 2025
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or Orthofix (OFIX). But which of these two stocks offers value investors a better bang fo
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Orthofix (OFIX) To Contact Him Directly To Discuss Their Options If you are a long-term st
FMS vs. OFIX: Which Stock Should Value Investors Buy Now?
12:40pm, Thursday, 07'th Aug 2025
Investors interested in Medical - Instruments stocks are likely familiar with Fresenius (FMS) and Orthofix (OFIX). But which of these two stocks presents investors with the better value opportunity ri
Orthofix (OFIX) Q2 Revenue Rises 2%
10:16pm, Tuesday, 05'th Aug 2025
Orthofix (OFIX) Q2 Revenue Rises 2%
Orthofix Medical Inc. (OFIX) Q2 2025 Earnings Call Transcript
11:18am, Tuesday, 05'th Aug 2025
Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Julie B. Andrews - Chief Financial Officer Julie D.
Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates
09:25am, Tuesday, 05'th Aug 2025
Orthofix (OFIX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.05 per share a year ago.
Orthofix Reports Second Quarter 2025 Financial Results
07:00am, Tuesday, 05'th Aug 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, a
Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference
07:00am, Wednesday, 16'th Jul 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate at the Canaccord Genuity 45th An
Orthofix to Report Second Quarter 2025 Financial Results
07:00am, Tuesday, 15'th Jul 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on
Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System
07:00am, Tuesday, 17'th Jun 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the global commercial launch of the TrueLok™ Elevate Transverse
Orthofix Medical Inc. (OFIX) Q1 2025 Earnings Call Transcript
02:39pm, Tuesday, 06'th May 2025
Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Julie Dewey - Chief Investor Relations and Communications Officer Massimo Calafiore -
